Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t be completed by the end of the year and that a trial for a different form of MS didn’t succeed.
www.marketwatch.com
#Sanofi #stock #slumps #setbacks #multiplesclerosis #drug
Sanofi stock slumps after two setbacks on multiple-sclerosis drug
